Key clinical point: Anticoagulants may be preferable to antiplatelet therapy for preventing leaflet thrombosis in low-risk transcatheter aortic valve replacement.
Major finding: At 30 days, leaflet thrombosis, a feared threat to valve longevity, was less common (4.7% vs. 16.3%; P = .07) on anticoagulation.
Data Source: A prospective randomized trial.
Disclosures: Dr. Rogers reported financial relationships with Edwards Lifesciences and Medtronic.
Rogers T et al. CRT 2020.